{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:55:34Z","timestamp":1771484134065,"version":"3.50.1"},"reference-count":133,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Uveal melanoma (UM) is a rare disease, but the most common primary intraocular cancer, mostly localized in the choroid. Currently, the first-line treatment options for UM are radiation therapy, resection, and enucleation. However, although these treatments could potentially be curative, half of all patients will develop metastatic disease, whose prognosis is still poor. Indeed, effective therapeutic options for patients with advanced or metastatic disease are still lacking. Recently, the development of new treatment modalities with a lower incidence of adverse events, a better disease control rate, and new therapeutic approaches, have merged as new potential and promising therapeutic strategies. Additionally, several clinical trials are ongoing to find new therapeutic options, mainly for those with metastatic disease. Many interventions are still in the preliminary phases of clinical development, being investigated in phase I trial or phase I\/II. The success of these trials could be crucial for changing the prognosis of patients with advanced\/metastatic UM. In this systematic review, we analyzed all emerging and available literature on the new perspectives in the treatment of UM and patient outcomes; furthermore, their current limitations and more common adverse events are summarized.<\/jats:p>","DOI":"10.3390\/biomedicines9101311","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T01:59:47Z","timestamp":1632707987000},"page":"1311","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7152-2613","authenticated-orcid":false,"given":"Mario Damiano","family":"Toro","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Zurich, 8091 Zurich, Switzerland"},{"name":"Department of General and Pediatric Ophthalmology, Medical University of Lublin, 20079 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-269X","authenticated-orcid":false,"given":"Lucia","family":"Gozzo","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"},{"name":"Clinical Pharmacology Unit, Regional Pharmacovigilance Centre, University Hospital of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Tracia","sequence":"additional","affiliation":[{"name":"Plastic and Reconstructive Surgery Department, American Hospital Dubai, Dubai, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2311-9728","authenticated-orcid":false,"given":"Marco","family":"Cicci\u00f9","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences, Morphological and Functional Images, University of Messina, AOU \u2018G. Martino\u2019, 98124 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Drago","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"},{"name":"Clinical Pharmacology Unit, Regional Pharmacovigilance Centre, University Hospital of Catania, 95123 Catania, Italy"},{"name":"Centre for Research and Consultancy in HTA and Drug Regulatory Affairs (CERD), University of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4879-4140","authenticated-orcid":false,"given":"Claudio","family":"Bucolo","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"},{"name":"Center of Research in Ocular Pharmacology\u2014CERFO, University of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresio","family":"Avitabile","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3321-2723","authenticated-orcid":false,"given":"Robert","family":"Rejdak","sequence":"additional","affiliation":[{"name":"Department of General and Pediatric Ophthalmology, Medical University of Lublin, 20079 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Nowomiejska","sequence":"additional","affiliation":[{"name":"Department of General and Pediatric Ophthalmology, Medical University of Lublin, 20079 Lublin, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-1774","authenticated-orcid":false,"given":"Sandrine","family":"Zweifel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yacoub A.","family":"Yousef","sequence":"additional","affiliation":[{"name":"Department of Surgery\/Ophthalmology, King Hussein Cancer Center, Amman 11941, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashed","family":"Nazzal","sequence":"additional","affiliation":[{"name":"Shami Eye Center, Amman 11941, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8722-7835","authenticated-orcid":false,"given":"Giovanni Luca","family":"Romano","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy"},{"name":"Center of Research in Ocular Pharmacology\u2014CERFO, University of Catania, 95123 Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"ref_1","unstructured":"DeVita, J.V.T., Lawrence, T.S., and Rosenberg, S.A. (2014). Intraocular melanoma. Cancer: Principles and Practice of Oncology, Wolter Kluwer, Lippincott, Williams and Wilkins. [10th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/15384047.2015.1046021","article-title":"miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications","volume":"16","author":"Ragusa","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","article-title":"Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases","volume":"32","author":"Shields","year":"2012","journal-title":"Retina"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaapos.2011.10.012","article-title":"Iris melanoma: Features and prognosis in 317 children and adults","volume":"16","author":"Shields","year":"2012","journal-title":"J. AAPOS"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/jcp.2005.033613","article-title":"Malignant melanoma of the ciliary body presenting as extraocular metastasis in the temporalis muscle","volume":"60","author":"Oittinen","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archopht.119.7.969","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS Report No. 18","volume":"119","author":"Earle","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"American Brachytherapy Society\u2014Ophthalmic Oncology Task Force, and ABS\u2014OOTF Committee (2014). The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy, 13, 1\u201314.","DOI":"10.1016\/j.brachy.2014.02.230"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/archopht.1982.01030030936007","article-title":"Proton beam irradiation of uveal melanomas. Results of 5 1\/2-year study","volume":"100","author":"Gragoudas","year":"1982","journal-title":"Arch. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6161","DOI":"10.1118\/1.4749933","article-title":"Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: Report of Task Group 129 by the AAPM and ABS","volume":"39","author":"Astrahan","year":"2012","journal-title":"Med. Phys."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0039-6257(97)00088-X","article-title":"Radiation therapy for choroidal melanoma","volume":"42","author":"Finger","year":"1997","journal-title":"Surv. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ceravolo, I., Oliverio, G.W., Alibrandi, A., Bhatti, A., Trombetta, L., Rejdak, R., Toro, M.D., and Trombetta, C.J. (2020). The Application of Structural Retinal Biomarkers to Evaluate the Effect of Intravitreal Ranibizumab and Dexamethasone Intravitreal Implant on Treatment of Diabetic Macular Edema. Diagnostics, 10.","DOI":"10.3390\/diagnostics10060413"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e19623","DOI":"10.1097\/MD.0000000000019623","article-title":"Coats\u2019 disease: Characteristics, management, outcome, and scleral external drainage with anterior chamber maintainer for stage 3b disease","volume":"99","author":"Yousef","year":"2020","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.2174\/1381612821666150909100212","article-title":"Intravitreal Steroids for the Prevention of PVR After Surgery for Retinal Detachment","volume":"21","author":"Gagliano","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/IAE.0b013e3182a0e446","article-title":"Treatment of persistent serous retinal detachment in Vogt-Koyanagi-Harada syndrome with intravitreal bevacizumab during the systemic steroid treatment","volume":"34","author":"Reibaldi","year":"2014","journal-title":"Retina (Phila. Pa.)"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000351176","article-title":"Rhegmatogenous Retinal Detachment with a High Risk of Proliferative Vitreoretinopathy Treated with Episcleral Surgery and an Intravitreal Dexamethasone 0.7-mg Implant","volume":"4","author":"Reibaldi","year":"2013","journal-title":"Case Rep. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000336273","article-title":"Resolution of Persistent Cystoid Macular Edema due to Central Retinal Vein Occlusion in a Vitrectomized Eye following Intravitreal Implant of Dexamethasone 0.7 mg","volume":"3","author":"Reibaldi","year":"2012","journal-title":"Case Rep. Ophthalmol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000337144","article-title":"Radiation Macular Edema after Ru-106 Plaque Brachytherapy for Choroidal Melanoma Resolved by an Intravitreal Dexamethasone 0.7-mg Implant","volume":"3","author":"Russo","year":"2012","journal-title":"Case Rep. Ophthalmol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.3928\/23258160-20200401-06","article-title":"Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy","volume":"51","author":"Rayess","year":"2020","journal-title":"Ophthalmic Surg. Lasers Imaging Retin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajo.2016.04.024","article-title":"Antiangiogenic or Corticosteroid Treatment in Patients With Radiation Maculopathy After Proton Beam Therapy for Uveal Melanoma","volume":"168","author":"Seibel","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1167\/iovs.10-5598","article-title":"In Vivo Ocular Efficacy Profile of Mapracorat, a Novel Selective Glucocorticoid Receptor Agonist, in Rabbit Models of Ocular Disease","volume":"52","author":"Shafiee","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ophtha.2008.12.027","article-title":"Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients","volume":"116","author":"Finger","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Collaborative Ocular Melanoma Study Group (2006). The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch. Ophthalmol., 124, 1684\u20131693.","DOI":"10.1001\/archopht.124.12.1684"},{"key":"ref_24","unstructured":"Straatsma, B.R. (2002). The Jules Francois Memorial lecture. The collaborative ocular melanoma study and management of choroidal melanoma. Bull. Soc. Belg. Ophtalmol., 5\u201311."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0161-6420(02)01277-0","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19","volume":"109","author":"Jampol","year":"2002","journal-title":"Ophthalmology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ajo.2004.07.006","article-title":"The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24","volume":"138","author":"Hawkins","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"696787","DOI":"10.3389\/fphar.2021.696787","article-title":"Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma","volume":"12","author":"Yousef","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/OPTH.S282741","article-title":"Management and Outcomes of Unilateral Group D Tumors in Retinoblastoma","volume":"15","author":"Amin","year":"2021","journal-title":"Clin. Ophthalmol. (Auckl. N.Z.)"},{"key":"ref_29","first-page":"1362","article-title":"Sigma1 recognition sites in rabbit iris-ciliary body: Topical sigma1-site agonists lower intraocular pressure","volume":"289","author":"Bucolo","year":"1999","journal-title":"J. Pharm. Exp."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"91099","DOI":"10.18632\/oncotarget.19556","article-title":"Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma","volume":"8","author":"Longhitano","year":"2017","journal-title":"Oncotarget"},{"key":"ref_31","first-page":"e123","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajo.2020.03.045","article-title":"Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes","volume":"216","author":"Schefler","year":"2020","journal-title":"Am. J. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.oret.2019.02.009","article-title":"Aflibercept for Radiation Maculopathy Study: A Prospective, Randomized Clinical Study","volume":"3","author":"Murray","year":"2019","journal-title":"Ophthalmol. Retin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ophtha.2009.01.051","article-title":"Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: A randomized controlled trial","volume":"116","author":"Horgan","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jvir.2012.04.027","article-title":"Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: Tumor response and predictive value of diffusion-weighted MR imaging in five patients","volume":"23","author":"Venturini","year":"2012","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1245\/s10434-013-3304-z","article-title":"Isolated hepatic perfusion for ocular melanoma metastasis: Registry data suggests a survival benefit","volume":"21","author":"Olofsson","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): A multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ejso.2014.06.010","article-title":"Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study","volume":"40","author":"Vahrmeijer","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1148\/radiol.2521081252","article-title":"High-dose immunoembolization: Survival benefit in patients with hepatic metastases from uveal melanoma","volume":"252","author":"Yamamoto","year":"2009","journal-title":"Radiology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.ejrad.2009.03.064","article-title":"Transarterial chemoembolization of liver metastases in patients with uveal melanoma","volume":"74","author":"Huppert","year":"2010","journal-title":"Eur. J. Radiol."},{"key":"ref_41","first-page":"131","article-title":"Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study","volume":"23","author":"Fiorentini","year":"2009","journal-title":"Vivo"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/CMR.0b013e32830317de","article-title":"Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients","volume":"18","author":"Voelter","year":"2008","journal-title":"Melanoma Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1245\/s10434-008-9881-6","article-title":"Isolated hepatic perfusion with 200 mg melphalan for advanced noncolorectal liver metastases","volume":"15","author":"Hoekman","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00008390-200402000-00011","article-title":"Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver","volume":"14","author":"Noter","year":"2004","journal-title":"Melanoma Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/PL00012075","article-title":"Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: A single-center experience with seven patients","volume":"6","author":"Egerer","year":"2001","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/CMR.0000000000000635","article-title":"Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: A two-stage single-centre phase II single-arm study","volume":"30","author":"Hussain","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00008390-199510000-00009","article-title":"Photodynamic therapy: A 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture","volume":"5","author":"Favilla","year":"1995","journal-title":"Melanoma Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s10147-020-01618-9","article-title":"Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma","volume":"25","author":"Nomura","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-19-1223","article-title":"Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)","volume":"26","author":"Luke","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1158\/1078-0432.CCR-19-0578","article-title":"First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed\/Refractory Solid Tumors","volume":"25","author":"Sachdev","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/bjophthalmol-2019-314461","article-title":"A prospective trial of adjuvant therapy for high-risk uveal melanoma: Assessing 5-year survival outcomes","volume":"104","author":"Binkley","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"114","DOI":"10.6004\/jnccn.2018.7070","article-title":"Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis","volume":"17","author":"Johnson","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/CMR.0000000000000509","article-title":"Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma","volume":"28","author":"Shah","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_54","first-page":"352","article-title":"A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients","volume":"30","author":"Garcia","year":"2019","journal-title":"Hum. Gene"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/CMR.0000000000000401","article-title":"Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: A single institution phase II study","volume":"27","author":"Schinzari","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/bjc.2016.419","article-title":"Phase II randomised discontinuation trial of the MET\/VEGF receptor inhibitor cabozantinib in metastatic melanoma","volume":"116","author":"Daud","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2016.68.1106","article-title":"Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors","volume":"34","author":"Naing","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10637-016-0391-2","article-title":"A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors","volume":"35","author":"Adjei","year":"2017","journal-title":"Investig. New Drugs"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bjc.2016.119","article-title":"Sorafenib in metastatic uveal melanoma: Efficacy, toxicity and health-related quality of life in a multicentre phase II study","volume":"115","author":"Mouriaux","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/CMR.0000000000000234","article-title":"A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma","volume":"26","author":"Shoushtari","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A phase 2 study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Zimmer, L., Vaubel, J., Mohr, P., Hauschild, A., Utikal, J., Simon, J., Garbe, C., Herbst, R., Enk, A., and Kampgen, E. (2015). Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118564"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4143\/crt.2014.261","article-title":"Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine","volume":"47","author":"Lee","year":"2015","journal-title":"Cancer Res. Treat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10637-014-0191-5","article-title":"Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors","volume":"33","author":"Dickson","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CMR.0b013e3283403ce9","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma","volume":"20","author":"Homsi","year":"2010","journal-title":"Melanoma Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/jir.2010.0054","article-title":"Gene regulatory and clinical effects of interferon beta in patients with metastatic melanoma: A phase II trial","volume":"31","author":"Borden","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00262-011-1089-0","article-title":"Ipilimumab in pretreated patients with metastatic uveal melanoma: Safety and clinical efficacy","volume":"61","author":"Danielli","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1158\/1078-0432.CCR-11-1463","article-title":"Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin","volume":"17","author":"Tarhini","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Bhatia, S., Moon, J., Margolin, K.A., Weber, J.S., Lao, C.D., Othus, M., Aparicio, A.M., Ribas, A., and Sondak, V.K. (2012). Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048787"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10637-012-9862-2","article-title":"Phase I\/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma","volume":"31","author":"Ott","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/CMR.0b013e328358b373","article-title":"A pilot study of sunitinib malate in patients with metastatic uveal melanoma","volume":"22","author":"Mahipal","year":"2012","journal-title":"Melanoma Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/j.ophtha.2009.04.044","article-title":"Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis","volume":"116","author":"Lane","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-08-2243","article-title":"Overexpression of the KIT\/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate","volume":"15","author":"Hofmann","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/CMR.0b013e328311aaa1","article-title":"A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma","volume":"18","author":"Bedikian","year":"2008","journal-title":"Melanoma Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/annonc\/mdl309","article-title":"A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma","volume":"17","author":"Schmittel","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s00347-006-1350-7","article-title":"Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma","volume":"103","author":"Richtig","year":"2006","journal-title":"Ophthalmologe"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.cmr.0000205017.38859.07","article-title":"A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma","volume":"16","author":"Butt","year":"2006","journal-title":"Melanoma Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00008390-200510000-00014","article-title":"A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma","volume":"15","author":"Schmittel","year":"2005","journal-title":"Melanoma Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/sj.bjc.6602586","article-title":"Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients","volume":"92","author":"Corrie","year":"2005","journal-title":"Br. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00008390-200506000-00010","article-title":"Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma","volume":"15","author":"Schmittel","year":"2005","journal-title":"Melanoma Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00008390-200412000-00001","article-title":"A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma","volume":"14","author":"Schmittel","year":"2004","journal-title":"Melanoma Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.ejca.2004.04.031","article-title":"A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours","volume":"40","author":"Keilholz","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00432-004-0569-4","article-title":"Clinical evaluation of in vitro chemosensitivity testing: The example of uveal melanoma","volume":"130","author":"Terheyden","year":"2004","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00001813-200306000-00002","article-title":"Treosulfan and gemcitabine in metastatic uveal melanoma patients: Results of a multicenter feasibility study","volume":"14","author":"Pfohler","year":"2003","journal-title":"Anticancer Drugs"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00008390-200306000-00013","article-title":"Phase II evaluation of temozolomide in metastatic choroidal melanoma","volume":"13","author":"Bedikian","year":"2003","journal-title":"Melanoma Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0959-8049(03)00132-1","article-title":"Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma","volume":"39","author":"Kivela","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/cncr.10996","article-title":"Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma","volume":"95","author":"Pyrhonen","year":"2002","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.bjc.6600521","article-title":"Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2","volume":"87","author":"Becker","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00001813-200202000-00009","article-title":"Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma","volume":"13","author":"Ellerhorst","year":"2002","journal-title":"Anticancer Drugs"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0936-6555(96)80117-8","article-title":"Oral indomethacin and ranitidine in advanced melanoma: A phase II study","volume":"8","author":"Mertens","year":"1996","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10637-008-9143-2","article-title":"O-Mel-Inib: A Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma","volume":"26","author":"Penel","year":"2008","journal-title":"Investig. New Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.preteyeres.2013.04.001","article-title":"Nanomedicines for back of the eye drug delivery, gene delivery, and imaging","volume":"36","author":"Kompella","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_97","first-page":"1215","article-title":"Nanomedicine in the application of uveal melanoma","volume":"9","author":"You","year":"2016","journal-title":"Int. J. Ophthalmol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.biopha.2018.08.138","article-title":"A review on recent drug delivery systems for posterior segment of eye","volume":"107","author":"Nayak","year":"2018","journal-title":"Biomed. Pharm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0928-0987(97)00023-7","article-title":"Biodegradable microspheres for the intravitreal administration of acyclovir: In vitro\/in vivo evaluation","volume":"5","author":"Conti","year":"1997","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4155\/tde.10.40","article-title":"Recent advances in ophthalmic drug delivery","volume":"1","author":"Kompella","year":"2010","journal-title":"Ther. Deliv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1167\/iovs.13-13707","article-title":"Drug and gene delivery to the back of the eye: From bench to bedside","volume":"55","author":"Durazo","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Beiu, C., Giurcaneanu, C., Grumezescu, A.M., Holban, A.M., Popa, L.G., and Mihai, M.M. (2020). Nanosystems for Improved Targeted Therapies in Melanoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020318"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"635101","DOI":"10.3389\/fphar.2021.635101","article-title":"Epiretinal Membrane Vitrectomy With and Without Intraoperative Intravitreal Dexamethasone Implant: A Systematic Review With Meta-Analysis","volume":"12","author":"Fallico","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000367715","article-title":"Adjuvant Therapy of Uveal Melanoma: Current Status","volume":"1","author":"Triozzi","year":"2014","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ohc.2004.07.002","article-title":"Uveal melanoma: Epidemiologic aspects","volume":"18","author":"Singh","year":"2005","journal-title":"Ophthalmol. Clin. N. Am."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: Epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.ophtha.2007.06.012","article-title":"Cytogenetics of uveal melanoma: A 7-year clinical experience","volume":"114","author":"Damato","year":"2007","journal-title":"Ophthalmology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.compbiomed.2018.09.024","article-title":"Prognostication of metastatic death in uveal melanoma patients: A Markov multi-state model","volume":"102","author":"Eleuteri","year":"2018","journal-title":"Comput. Biol. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10384-019-00656-9","article-title":"Clinical predictors of survival in metastatic uveal melanoma","volume":"63","author":"Lorenzo","year":"2019","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00280-019-03860-z","article-title":"Uveal melanoma: Physiopathology and new in situ-specific therapies","volume":"84","author":"Souto","year":"2019","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_111","unstructured":"NCCN (2021, August 01). N.C.C.N. Uveal Melanoma. Version 2, Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1488."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic Therapy for Melanoma: ASCO Guideline","volume":"38","author":"Seth","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_113","first-page":"1758834018757175","article-title":"Treatment of uveal melanoma: Where are we now?","volume":"10","author":"Yang","year":"2018","journal-title":"Adv. Med. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ctrv.2012.01.002","article-title":"Uveal melanoma","volume":"38","author":"Spagnolo","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CMR.0b013e3283610586","article-title":"Treatment of metastatic uveal melanoma with intravenous fotemustine","volume":"23","author":"Spagnolo","year":"2013","journal-title":"Melanoma Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10198-018-1007-x","article-title":"Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare","volume":"20","author":"Jonsson","year":"2019","journal-title":"Eur. J. Health Econ. HEPAC Health Econ. Prev. Care"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/TACG.S69210","article-title":"The genetics of uveal melanoma: Current insights","volume":"9","author":"Helgadottir","year":"2016","journal-title":"Appl. Clin. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/imt-2017-0066","article-title":"PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma","volume":"9","author":"Javed","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","article-title":"Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma","volume":"24","author":"Maio","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3109\/0284186X.2013.786839","article-title":"Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)","volume":"52","author":"Kelderman","year":"2013","journal-title":"Acta Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience","volume":"119","author":"Luke","year":"2013","journal-title":"Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1200\/jco.2014.32.15_suppl.9033","article-title":"Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial","volume":"32","author":"Codes","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study","volume":"39","author":"Pelster","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Damato, B.E., Dukes, J., Goodall, H., and Carvajal, R.D. (2019). Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers, 11.","DOI":"10.3390\/cancers11070971"},{"key":"ref_127","unstructured":"ESMO (2021, January 15). Promising Results are Provided by Tebentafusp in Metastatic Uveal Melanoma. Available online: https:\/\/www.esmo.org\/oncology-news\/promising-results-are-provided-by-tebentafusp-in-metastatic-uveal-melanoma."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Sacco, J.J., Carvajal, R., Butler, M.O., Shoushtari, A.N., Hassel, J.C., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., and Piulats Rodriguez, J.M. (2021, January 15). A Phase (ph) II, Multi-Center Study of the Safety and Efficacy of Tebentafusp (Tebe) (IMCgp100) in Patients (pts) with Metastatic Uveal Melanoma (mUM). Available online: https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-immuno-oncology-virtual-congress-2020\/a-phase-ph-ii-multi-center-study-of-the-safety-and-efficacy-of-tebentafusp-tebe-imcgp100-in-patients-pts-with-metastatic-uveal-melanoma-mum.","DOI":"10.1016\/j.annonc.2020.10.552"},{"key":"ref_129","unstructured":"Immunocore (2021, January 15). Novel Immunotherapy Tebentafusp Granted Fast Track Designation for Metastatic Uveal Melanoma. Available online: https:\/\/www.targetedonc.com\/view\/novel-immunotherapy-tebentafusp-granted-fast-track-designation-for-metastatic-uveal-melanoma."},{"key":"ref_130","unstructured":"Immunocore (2021, January 15). Immunocore\u2019s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma. Available online: https:\/\/bit.ly\/2UUPKNU."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Vivet-Noguer, R., Tarin, M., Roman-Roman, S., and Alsafadi, S. (2019). Emerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology. Cancers, 11.","DOI":"10.3390\/cancers11071019"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Russo, A., Ragusa, M., Barbagallo, C., Longo, A., Avitabile, T., Uva, M.G., Bonfiglio, V., Toro, M.D., Caltabiano, R., and Mariotti, C. (2017). miRNAs in the vitreous humor of patients affected by idiopathic epiretinal membrane and macular hole. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174297"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1167\/tvst.9.6.23","article-title":"MicroRNAs in the Vitreous Humor of Patients with Retinal Detachment and a Different Grading of Proliferative Vitreoretinopathy: A Pilot Study","volume":"9","author":"Toro","year":"2020","journal-title":"Transl. Vis. Sci. Technol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1311\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:04:41Z","timestamp":1760166281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":133,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["biomedicines9101311"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9101311","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]}}}